Press release
Systemic Lupus Erythematosus Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | GSK, AstraZeneca, Eli Lilly and Company, Biogen, Xencor, Idorsia Pharma
DelveInsight's "Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Systemic Lupus Erythematosus market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Systemic Lupus Erythematosus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Lupus Erythematosus Market Forecast [https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Key Highlights from Systemic Lupus Erythematosus market Report:
*
The Systemic Lupus Erythematosus market size was valued ~USD 3,200 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In March 2025, Merck KGaA's oral TLR7/8 inhibitor, enpatoran, did not achieve the primary endpoint in a subgroup of patients; however, the company plans to continue its development. As disclosed during the Q4 earnings call, enpatoran did not meet the primary endpoint-BILAG-Based Composite Lupus Assessment (BICLA) response at 24 weeks-in patients with systemic lupus erythematosus (SLE). The WILLOW trial (NCT05162586), a randomized, double-blind, placebo-controlled study, is evaluating the drug in 456 patients diagnosed with cutaneous lupus erythematosus (CLE) and SLE.
*
In October 2024, The FDA granted approval for Cullinan Therapeutics' investigational new drug (IND) application for CLN-978, intended for the treatment of systemic lupus erythematosus (SLE).
*
In September 2024, Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced today that it has received approval from the Human Research Ethics Committee (HREC) in Australia to begin its global Phase 1 clinical trial. The trial will evaluate CLN-978, a CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE).
*
The United States holds the largest market size for systemic lupus erythematosus, approximately USD 2,600 million, compared to the EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.
*
Prominent companies in the Systemic Lupus Erythematosus (SLE) market, including Novartis/MorphoSys, Idorsia Pharmaceuticals/Viatris, RemeGen, and Biogen, are striving to enhance treatment options for SLE. In August 2023, AbbVie launched its Phase III Select-SLE trial to assess the efficacy of RINVOQ in treating moderate to severe SLE.
*
The 40-59 years age group is the most impacted by the prevalence of systemic lupus erythematosus. In 2023, across the 7MM, around 40% of the total cases were found in this age group.
*
In 2023, about 50% of the cases in Spain were classified as moderate.
*
Key Systemic Lupus Erythematosus Companies: GlaxoSmithKline, AstraZeneca, ImmuPharma, Biogen, UCB Pharma and Biogen, Hoffmann-La Roche, Idorsia, Daiichi Sankyo, Inc., Jemincare, Alpine Immune Sciences, Inc., Bristol-Myers Squibb, AstraZeneca, Beijing Mabworks Biotech, Janssen Research & Development, Novartis, Biogen, Galapagos NV, Eli Lilly and Company, Eisai Co., Ltd., Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
*
Key Systemic Lupus Erythematosus Therapies: BENLYSTA (belimumab), SAPHNELO (anifrolumab), Lupuzor, Litifilimab (BIIB059), Dapirolizumab pegol, GAZYVA, Cenerimod, DS-7011a, JMKX000189, ALPN-101, BMS-986165, Medi-546, MIL62, Nipocalimab, ianalumab, BIIB059 (litifilimab), GLPG3667, LY3471851, E6742, Obinutuzumab, Cenerimod and others
*
The Systemic Lupus Erythematosus epidemiology based on gender analyzed that Systemic Lupus Erythematosus is more prevalent in females
*
The Systemic Lupus Erythematosus market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Lupus Erythematosus pipeline products will significantly revolutionize the Systemic Lupus Erythematosus market dynamics.
Systemic Lupus Erythematosus Overview:
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues and organs. It can affect various parts of the body, including the skin, joints, kidneys, brain, and other organs. Common symptoms include fatigue, joint pain, skin rashes, and fever. The cause is not fully understood but involves a combination of genetic, hormonal, and environmental factors. SLE is more common in women and often requires long-term management with medications such as anti-inflammatories, immunosuppressants, and corticosteroids to control inflammation and prevent flare-ups.
Get a Free sample for the Systemic Lupus Erythematosus Market Report:
https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market [https://www.delveinsight.com/report-store/systemic-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Systemic Lupus Erythematosus Epidemiology Insights:
The epidemiology segment for Systemic Lupus Erythematosus offers information on the past and present patient populations affected by the condition and predicts future trends across seven significant countries. It aids in understanding the factors driving current and anticipated trends by examining various studies and insights from key opinion leaders.
Systemic Lupus Erythematosus Epidemiology Segmentation:
The Systemic Lupus Erythematosus market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Systemic Lupus Erythematosus
*
Prevalent Cases of Systemic Lupus Erythematosus by severity
*
Gender-specific Prevalence of Systemic Lupus Erythematosus
*
Diagnosed Cases of Episodic and Chronic Systemic Lupus Erythematosus
Download the report to understand which factors are driving Systemic Lupus Erythematosus epidemiology trends @ Systemic Lupus Erythematosus Epidemiology Forecast [https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Systemic Lupus Erythematosus Therapies and Key Companies
*
BENLYSTA (belimumab): GlaxoSmithKline
*
SAPHNELO (anifrolumab): AstraZeneca
*
Lupuzor: ImmuPharma
*
Litifilimab (BIIB059): Biogen
*
Dapirolizumab pegol: UCB Pharma and Biogen
*
GAZYVA: Hoffmann-La Roche
*
Cenerimod: Idorsia
*
DS-7011a: Daiichi Sankyo, Inc.
*
JMKX000189: Jemincare
*
ALPN-101: Alpine Immune Sciences, Inc.
*
BMS-986165: Bristol-Myers Squibb
*
Medi-546: AstraZeneca
*
MIL62: Beijing Mabworks Biotech
*
Nipocalimab: Janssen Research & Development
*
ianalumab: Novartis
*
BIIB059 (litifilimab): Biogen
*
GLPG3667: Galapagos NV
*
LY3471851: Eli Lilly and Company
*
E6742: Eisai Co., Ltd.
*
Obinutuzumab: Hoffmann-La Roche
*
Cenerimod: Idorsia Pharmaceuticals
Emerging Systemic Lupus Erythematosus drugs Uptake:
This section on Systemic Lupus Erythematosus concentrates on the adoption rate of newly introduced or anticipated Systemic Lupus Erythematosus medications within the market between 2020 and 2034. The evaluation includes the acceptance of these drugs within the Systemic Lupus Erythematosus market, patient adoption of various therapies, and the sales figures associated with each drug.
*
In September 2024, Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced today that it has received approval from the Human Research Ethics Committee (HREC) in Australia to begin its global Phase 1 clinical trial. The trial will evaluate CLN-978, a CD19xCD3 bispecific T cell engager, for the treatment of systemic lupus erythematosus (SLE).
*
Treatments of Systemic Lupus Erythematosus include NSAIDs and antimalarial agents, which are the first-line therapies for mild SLE. In addition, glucocorticoids and cytotoxic or immunosuppressive agents-such as azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine, and methotrexate -are used for SLE with organ involvement.
Discover more about therapies set to grab major Systemic Lupus Erythematosus market share @ Systemic Lupus Erythematosus Treatment Landscape [https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Systemic Lupus Erythematosus Market Forecast:
Presently, the market includes approved products for Systemic Lupus Erythematosus like BENLYSTA (belimumab) and SAPHNELO (anifrolumab-fnia).
The Systemic Lupus Erythematosus market drivers include - There is a robust pipeline for SLE with some drugs in the late stage of development, some with novel mechanisms of action, such as cenerimod, iberdomide, RSLV-132, etc. Many key players such as BMS, Pfizer, Amgen, etc., are also investigating their therapies in the mid and early stages, the diagnosed patient pool is expected to increase, which will boost the market in the coming years.
Scope of the Systemic Lupus Erythematosus Market Report:
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Systemic Lupus Erythematosus Companies: GlaxoSmithKline, AstraZeneca, ImmuPharma, Biogen, UCB Pharma and Biogen, Hoffmann-La Roche, Idorsia, Daiichi Sankyo, Inc., Jemincare, Alpine Immune Sciences, Inc., Bristol-Myers Squibb, AstraZeneca, Beijing Mabworks Biotech, Janssen Research & Development, Novartis, Biogen, Galapagos NV, Eli Lilly and Company, Eisai Co., Ltd., Hoffmann-La Roche, Idorsia Pharmaceuticals, and others
*
Key Systemic Lupus Erythematosus Therapies: BENLYSTA (belimumab), SAPHNELO (anifrolumab), Lupuzor, Litifilimab (BIIB059), Dapirolizumab pegol, GAZYVA, Cenerimod, DS-7011a, JMKX000189, ALPN-101, BMS-986165, Medi-546, MIL62, Nipocalimab, ianalumab, BIIB059 (litifilimab), GLPG3667, LY3471851, E6742, Obinutuzumab, Cenerimod, and others
*
Systemic Lupus Erythematosus Therapeutic Assessment: Systemic Lupus Erythematosus current marketed and Systemic Lupus Erythematosus emerging therapies
*
Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus market drivers and Systemic Lupus Erythematosus market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Systemic Lupus Erythematosus Unmet Needs, KOL's views, Analyst's views, Systemic Lupus Erythematosus Market Access and Reimbursement
To know more about Systemic Lupus Erythematosus companies working in the treatment market, visit @ Systemic Lupus Erythematosus Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Systemic Lupus Erythematosus Market Report Introduction
2. Executive Summary for Systemic Lupus Erythematosus
3. SWOT analysis of Systemic Lupus Erythematosus
4. Systemic Lupus Erythematosus Patient Share (%) Overview at a Glance
5. Systemic Lupus Erythematosus Market Overview at a Glance
6. Systemic Lupus Erythematosus Disease Background and Overview
7. Systemic Lupus Erythematosus Epidemiology and Patient Population
8. Country-Specific Patient Population of Systemic Lupus Erythematosus
9. Systemic Lupus Erythematosus Current Treatment and Medical Practices
10. Systemic Lupus Erythematosus Unmet Needs
11. Systemic Lupus Erythematosus Emerging Therapies
12. Systemic Lupus Erythematosus Market Outlook
13. Country-Wise Systemic Lupus Erythematosus Market Analysis (2020-2034)
14. Systemic Lupus Erythematosus Market Access and Reimbursement of Therapies
15. Systemic Lupus Erythematosus Market Drivers
16. Systemic Lupus Erythematosus Market Barriers
17. Systemic Lupus Erythematosus Appendix
18. Systemic Lupus Erythematosus Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=systemic-lupus-erythematosus-market-anticipated-to-expand-rapidly-during-20242034-says-delveinsight-gsk-astrazeneca-eli-lilly-and-company-biogen-xencor-idorsia-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Lupus Erythematosus Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight | GSK, AstraZeneca, Eli Lilly and Company, Biogen, Xencor, Idorsia Pharma here
News-ID: 3964045 • Views: …
More Releases from ABNewswire
Prompt Builder Launches Platform to Craft Perfect AI Prompts in Seconds, Not Hou …
Prompt Builder is a new AI prompt engineering platform that transforms plain-English ideas into optimized, ready-to-use prompts for large language models within seconds promptbuilder.cc. By eliminating trial-and-error and leveraging 1,000+ expert-crafted templates promptbuilder.cc, PromptBuilder empowers users to achieve high-quality, consistent AI-generated results faster and with minimal effort.
Canada, BC - September 15, 2025 - PromptBuilder carried out the worldwide launch of its platform for prompt engineering in AI, which enables prompt…
Invest in Tampa Bay's Future with High-Quality Remodeling and Custom Constructio …
NovaCore Builders, a Florida State Certified Building Contractor, delivers high-quality remodeling, renovations, and custom home construction across Tampa Bay. With expertise in kitchens, bathrooms, additions, concrete, masonry, and interior finishes, NovaCore helps homeowners and businesses enhance property value and resilience. Trusted by 54+ new clients in the past year, the company is committed to quality, clear communication, and building Tampa's future with care.
The Tampa bay housing market is undergoing a…
NYC Divorce Mediation Lawyer Juan Luciano Helps Entrepreneurs Protect Business I …
Divorce introduces unique challenges for entrepreneurs. NYC divorce mediation lawyer Juan Luciano (https://divorcelawfirmnyc.com/divorce-mediation-for-entrepreneurs/) provides a strategic alternative to litigation that reduces risk to business operations. At Juan Luciano Divorce Lawyer, services are focused on helping business owners navigate divorce while preserving the health of the business. For entrepreneurs in New York, divorce proceedings involving a business can threaten assets, company stability, workforce continuity, and long-term growth.
As an NYC divorce mediation…
New York City Divorce Mediation Lawyer Ryan Besinque Helps Families Navigate Pos …
Life after divorce often involves unexpected shifts - a new job, a move to another borough, or changes in a child's needs. For parents looking to revise their existing legal agreements, turning to a New York City divorce mediation lawyer can provide a more thoughtful path forward. Ryan Besinque (https://www.besinquelaw.com/how-to-modify-your-child-support-or-custody-agreement-with-post-divorce-mediation/) of The Law Office of Ryan Besinque guides clients through these post-divorce transitions with a focus on creating solutions that…
More Releases for Lupus
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
